Capital Flow Monitor · Sponsors · CIK 1997038
Iambic Therapeutics, Inc.
5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO, CA, 92121 · (619) 330-5499
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$125.0M
Sold
$99.3M
% sold
79.4%
Investors
22
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | D | 506(b) | $66.5M | $66.0M | 99.2% | 16 | EDGAR ↗ |
| 2026-04-08 | D | 506(b) | $50.0M | $27.8M | 55.5% | 7 | EDGAR ↗ |
| 2025-11-21 | D ·current | 506(b) | $125.0M | $99.3M | 79.4% | 22 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Thomas Miller — Executive Officer / Director, San Diego, CA
5 other raises
- SSGF I REIT Holdings, LLC $125K of $125K · 100.0%
- SREF VIII REIT Holdings, LLC $125K of $125K · 100.0%
- Stoltz Strategic Growth Fund I, L.P. $200.0M of $600.0M · 33.3%
- Haven Fund II LLC $2.5M of $50.0M · 5.0%
- Stoltz Real Estate Fund VIII, L.P. $72.5M of $300.0M · 24.2%
- Fred Manby — Executive Officer / Director, San Diego, CA
- Neil Josephson — Executive Officer, San Diego, CA
- Michael Secora — Executive Officer, San Diego, CA
-
Jishnu Bhattacharjee — Director, San Diego, CA
2 other raises
- ONEHOP INC $30.0M of $30.0M · 100.0%
- Nexus Ventures VIII, L.P. $0 of $700.0M · 0.0%
- Evan Rachlin — Director, San Diego, CA
-
R. Jacob Vogelstein — Director, San Diego, CA
15 other raises
- Catalio Access Fund XII, LLC $20.1M of $20.1M · 100.0%
- NextPoint Therapeutics, Inc. $33.7M of $48.7M · 69.2%
- Catalio Access Fund XI, LLC $16.3M of $16.3M · 100.0%
- Catalio Access Fund IX, LLC $17.3M of $17.3M · 100.0%
- Catalio Inflection Fund III, LLC $8.0M of $8.0M · 100.0%
- Catalio Inflection Fund II, LLC $10.0M of $10.0M · 100.0%
- Catalio Structured Opportunities Offshore Fund II, LP $122.8M of —
- Catalio Structured Opportunities Fund II, LP $179.3M of —
- Catalio Genesis Fund X, LLC $19.1M of $19.1M · 100.0%
- Catalio Access Fund X, LLC $20.3M of $20.3M · 100.0%
- Catalio Access Fund VIII, LLC $25.0M of $25.0M · 100.0%
- Catalio Public Equities Offshore Fund, Ltd. $142.1M of —
- Catalio Public Equities Fund, LP $83.9M of —
- Catalio Nexus Fund IV, LP $357.6M of —
- Catalio Genesis Fund IX, LLC $8.6M of $8.6M · 100.0%
- Mary Tagliaferri — Director, San Diego, CA
- William Rastetter — Director, San Diego, CA
-
Kurt von Emster — Director, San Diego, CA
1 other raise
- Jasper Therapeutics, Inc. $132.0M of $132.0M · 100.0%
- Shalini Sharp — Director, San Diego, CA
- Pete Olson — Executive Officer, San Diego, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.